CJC-1295 No DAC: A Syntetic Peptide of GHRH

by | Aug 8, 2022 | Research


CJC-1295 NO DAC has been shown to improve and balance water regulation in the body. The peptide is also an indigestion modulator.

Several modifications have been made to the Growth Hormone-Releasing Hormone to preserve and eliminate some of the hormone’s effects. CJC-1295, consisting of the first 25 amino acids of GHRH, is among those lists of modifications.

CJC-1295 is the synthetic equivalent of hGFR (1-29). It was created to produce a more soluble growth hormone secretagogue that is produced in ample amounts but retains the physiological features of GHRH.

The Difference Between CJC-1295 and CJC-1295 DAC

These two peptides seem similar but are not identical. CJC-1295 is a modified equivalent of the first 29 amino acids of GHRH, chemically identical to other growth hormone analogs like Sermorelin. Meanwhile, CJC-1295 DAC is created by adding the Drug Affinity Complex DAC, to CJC-1295.
DAC is added to CJC-1295 using the lysine linker. The DAC protects CJC-1295 while it circulates in the bloodstream. DAC ensures the long half-life of CJC-1295 by allowing the peptide to bind to blood proteins such as Albumin. 


The Functions of CJC-1295

CJC-1295 NO DAC functions to enhance protein synthesis. The peptide does this by inhibiting the natural process of cellular degradation, thereby increasing protein synthesis.
The peptide can also improve the lipolytic process in the human body by increasing the rate of synthesis and disintegration. By increasing the lipolytic process of the body, CJC-1295 NO DAC peptide causes the body to burn fat more efficiently.
CJC-1295 can also potentially enhance wound healing, increases bone density, and increase the rate of muscle growth.


How CJC-1295 Influences Hemorrhagic Shock and GHRH 1-29 Interaction

CJC-1295 NO DAC stimulates and improves nerve reflexes within the brain and modulates blood flow, thereby preventing acute organ failure following hemorrhagic shock. On the other hand, hemorrhagic shock is an acute condition followed by reduced tissue perfusion and insufficient nutrient and oxygen delivery necessary for cellular functions. Hemorrhagic shock is classified as cardiogenic, hypovolemic, septic, and neurogenic.


The Role of CJC-1295 NO DAC in Growth

The peptide is essential for maintaining the normal rate of growth hormone release.[1] By doing this, the peptide becomes vital therapy for abnormal growth in varieties of animal species. Maintaining the normal growth hormone level is critical to releasing downstream hormones like insulin-like growth factor-2 (IGF-1).
CJC-1295 significantly enhances the synthesis of IGF-1. GH, CJC-1295, and IGF-1 collectively influence the pro-inflammatory mechanisms when activated.
In mouse models of GHRH knockout, the administration of CJC-1295 effectively reduces growth deficits. Furthermore, administering CJC-1295 daily steadily enhanced the total body weight and length.[2] This study reports that “These findings demonstrate that treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice. The same dose is less effective when administered every 48 or 72 h.”
The peptide also assessed the abnormal response to GRF following obesity. 


How CJC-1295 NO DAC Influences Infertility

Scientists suggest GRF analogs, CJC-1295, can induce ovulation in infertile female patients. Facts state that ovulation is solely dependent on IGF-1 and regulated by the release and cycling of growth hormones. However, to prove this fact, research in mouse models of superovulation shows that the levels of IGF-1 and GH increase significantly with ovulation.[3] These results posit that the administration of a GH secretagogue like CJC-1295 can induce ovulation.
Scientific research also suggests that CJC-1295 NO DAC and other GHRH analogs can impact male infertility by inducing sperm production. However, note that this hypothesis is yet to be proven fact.[4] The researchers report that “these results led to the identification of CJC-1295 as a stable and active hGRF1-29 analogwith an extended plasma half-life.” 

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.



  1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702. Epub 2006 Oct 3. PMID: 17018654.
  2. Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006. Epub 2006 Jul 5. PMID: 16822960.
  3. Volpe A, Coukos G, Barreca A, Giordano G, Artini PG, Genazzani AR. Clinical use of growth hormone-releasing factor for induction of superovulation. Hum Reprod. 1991 Oct;6(9):1228-32. doi: 10.1093/oxfordjournals.humrep.a137517. PMID: 1752922.
  4. Jetté, Lucie, et al. “hGRF1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long Lasting GRF Analog.” (2005)
  5. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536. Epub 2005 Dec 13. PMID: 16352683.